Kathrin U Jansen was born on 1958 and is the former Head of Vaccine Research and Development at Pfizer.
17 Facts About Kathrin Jansen
1.
2.
Kathrin Jansen previously led the development of the HPV vaccine and newer versions of the pneumococcal conjugate vaccine, and is working with BioNTech to create a COVID-19 vaccine using mRNA that was approved for Emergency Use Authorization in the United States on December 11,2020.
3.
Kathrin Jansen was frequently unwell as a child, and suffered several throat infections.
4.
Kathrin Jansen's family fled to West Germany before the Berlin Wall was constructed in 1961.
5.
Kathrin Jansen eventually studied biology at the University of Marburg, with the hope to work in the pharmaceutical industry.
6.
Kathrin Jansen completed her doctoral degree at the University of Marburg, where she studied chemical pathways in bacteria.
7.
In particular, Kathrin Jansen focussed on the yeast expression of multi-subunit neuronal receptors.
8.
Kathrin Jansen was fascinated by the development of novel pharmaceuticals, and wanted to return to Europe, so moved to Geneva to join the Glaxo Institute for Molecular Biology.
9.
At the Glaxo Institute for Molecular Biology Jansen encouraged the immunologists to create a novel receptor for immunoglobulin E She completed an internship in the laboratory of David Bishop at the University of Oxford, where she studied the expression of insect cells using baculoviridae.
10.
Kathrin Jansen became interested in making vaccines, and started work on the human papillomavirus infection.
11.
Kathrin Jansen managed to convince Edward Scolnick that the experimental vaccine was worth pursuing, and started to make the assays.
12.
Kathrin Jansen worked with Laura Koutsky at the University of Washington to conduct natural history studies that informed the phase 2 clinical trials.
13.
Kathrin Jansen joined VaxGen in 2004, where she was appointed chief scientific officer.
14.
In 2006 Kathrin Jansen left VaxGen to join Wyeth Pharmaceuticals in 2006, where she was responsible for vaccine discovery.
15.
In 2010 Kathrin Jansen was appointed adjunct professor at the University of Pennsylvania.
16.
Kathrin Jansen looked at four potential candidates, before joining with BioNTech to improve the likelihood of identifying the vaccine with the highest potential.
17.
In July 2020 Kathrin Jansen announced positive results in their clinical trials, resulting in an increase in the share price of Pfizer.